Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Return on Sales (2021 - 2025)

Amylyx Pharmaceuticals has reported Return on Sales over the past 5 years, most recently at 239.74% for Q3 2025.

  • Quarterly results put Return on Sales at 239.74% for Q3 2025, down 6497.0% from a year ago — trailing twelve months through Sep 2025 was 239.74% (down 23820.0% YoY), and the annual figure for FY2024 was 0.0%, down 14.0%.
  • Return on Sales for Q3 2025 was 239.74% at Amylyx Pharmaceuticals, up from 518.9% in the prior quarter.
  • Over the last five years, Return on Sales for AMLX hit a ceiling of 103.24% in Q1 2025 and a floor of 538.08% in Q2 2022.
  • Median Return on Sales over the past 5 years was 81.2% (2021), compared with a mean of 162.52%.
  • Biggest five-year swings in Return on Sales: surged 53831bps in 2023 and later crashed -44783bps in 2025.
  • Amylyx Pharmaceuticals' Return on Sales stood at 308.44% in 2021, then surged by 102bps to 5.87% in 2022, then crashed by -98bps to 0.11% in 2023, then plummeted by -368546bps to 415.43% in 2024, then surged by 42bps to 239.74% in 2025.
  • The last three reported values for Return on Sales were 239.74% (Q3 2025), 518.9% (Q2 2025), and 103.24% (Q1 2025) per Business Quant data.